SAB Biotherapeutics Inc (SABS NASDAQ) stock market data APIs
$2.1216
-0.04(-1.9%)
as of September 12, 2025
Try our APIs with
free plan!
SAB Biotherapeutics Inc Financial Data Overview
Price chart is built with
Anychart
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Prev. Close
2.1216
Open
2.0835
High
2.1755
Low
2.0835
52 wk Range
1-5.01
Market Cap
22 072 K
Shares Outstanding
10 411 K
Revenue
115 K
EPS
-1.09
Beta
0.549
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SAB Biotherapeutics Inc data using free add-ons & libraries
Get SAB Biotherapeutics Inc Fundamental Data
SAB Biotherapeutics Inc Fundamental data includes:
- Net Revenue: 115 K
- EBITDA: -38 516 976
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SAB Biotherapeutics Inc News
New
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platf...
Which stocks are moving before the opening bell on Wednesday?
Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMEN...
SAB Biotherapeutics files to sell 250M shares of common stock for holders
* SAB Biotherapeutics (NASDAQ:SABS [https://seekingalpha.com/symbol/SABS]) filed to sell 250M shares of common stock for holders. * Filing [https://seekingalpha.com/filing/10374430] MORE ON SA...
Chardan Capital lowers SAB Biotherapeutics stock price target to $12 from $20
Investing.com - Chardan Capital Markets has lowered its price target on SAB Biotherapeutics (NASDAQ:SABS) stock to $12.00 from $20.00 while maintaining a Buy rating following the company’s second-qu...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
